tolvaptan has been researched along with pituitrin in 61 studies
Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (pituitrin) | Trials (pituitrin) | Recent Studies (post-2010) (pituitrin) |
---|---|---|---|---|---|
967 | 172 | 786 | 22,137 | 594 | 2,101 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 15 (24.59) | 29.6817 |
2010's | 32 (52.46) | 24.3611 |
2020's | 14 (22.95) | 2.80 |
Authors | Studies |
---|---|
Gheorghiade, M; Orlandi, C; Zimmer, CA | 1 |
Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC; Orlandi, C; Ouyang, J; Smith, WB; Zimmer, CA | 1 |
Greenberg, A; Verbalis, JG | 1 |
Gross, P; Quittnat, F | 1 |
Kamyar, M; Lemmens-Gruber, R | 1 |
Gross, P; Herbrig, K; Palm, C; Pistrosch, F | 1 |
Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ | 1 |
Bricmont, P; Mallikaarjun, S; Shoaf, SE; Wang, Z | 1 |
Aki, S; Furuta, T; Minamikawa, J; Nishi, T; Torisawa, Y | 1 |
Hobbs, RE; Tang, WH | 1 |
Laczi, F | 1 |
Farmakis, D; Filippatos, G; Gheorghiade, M; Kremastinos, DT; Parissis, J | 1 |
Whellan, DJ | 1 |
Blair, JE; Burnett, JC; Cook, T; Gheorghiade, M; Grinfeld, L; Konstam, MA; Krasa, H; Maggioni, AP; Orlandi, C; Swedberg, K; Traver, B; Udelson, JE; Zannad, F; Zimmer, C | 1 |
Gross, P; Herbrig, K; Marczewski, T | 1 |
Dhalla, NS; Rehsia, NS | 1 |
Reilly, T; Schork, MR | 1 |
Singh, M; Slawsky, MT; Valania, G | 1 |
Villabona, C | 1 |
Hix, J; Sterns, R | 1 |
Hori, M | 1 |
Fujiki, H; Nivens, E; Pinto, CS; Reif, GA; Wallace, DP; Yamaguchi, T | 1 |
Bilsker, M; Hauptman, PJ; Konstam, MA; O'Brien, T; Orlandi, C; Sequeira, R; Thomas, I; Udelson, JE; Zimmer, C | 1 |
Akioka, Y; Fujita, T; Hashimoto, M; Hisano, M; Igarashi, T; Iida, A; Iiri, T; Makita, N; Manaka, K; Miura, K; Sekine, T; Takahashi, K; Takubo, N; Ueda, N | 1 |
Inomata, T | 1 |
de Boer, H; Janssens, PM; Roelofsen, A | 1 |
Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Nodari, S; Subacius, HP; Swedberg, K; Vaduganathan, M; Zannad, F | 1 |
Bhatt, DL; Cavender, MA | 1 |
Ambrosy, AP; Butler, J; Fonarow, GC; Gheorghiade, M; Konstam, MA; Maggioni, A; Mentz, RJ; Subacius, H; Swedberg, K; Vaduganathan, M; Zannad, F | 1 |
Bankir, L; Bouby, N; Ritz, E | 1 |
Buehrer, BA; Cassell, MD; Davis, DR; Grobe, JL; Hilzendeger, AM; Ketsawatsomkron, P; Li, H; Littlejohn, NK; Liu, X; Pearson, NA; Pelham, CJ; Siel, RB; Sigmund, CD; Thompson, AP; Weidemann, BJ | 1 |
Hew-Butler, T; Hummel, J; Rider, BC; Verbalis, JG | 1 |
Al Therwani, S; Bech, JN; Jensen, JM; Mose, FH; Pedersen, EB | 1 |
Adams, KF; Lin, TE; Patterson, JH | 1 |
Egami, N; Kakigi, A; Takeda, T; Yamasoba, T | 1 |
Chen, C; Chen, RP; Huang, XL; Huang, ZM; Lin, HH; Zhang, WY | 1 |
Nitta, D | 1 |
Izumi, N; Kurosaki, M; Nakanishi, H | 1 |
Tesař, V | 1 |
Gustafsson, F; Vishram-Nielsen, JK | 1 |
De Rechter, S; Janssens, P; Liebau, MC; Mekahli, D; Weydert, C; Wissing, KM | 1 |
Torres, VE; van Gastel, MDA | 1 |
Garrahy, A; Hannon, AM; Thompson, CJ; Williams, DJ; Zia-Ul-Hussnain, HM | 1 |
Jolobe, OMP | 1 |
Sterns, RH | 1 |
Han, Q; Liu, M; Yang, J | 1 |
Mohieldin, AM; Nauli, SM; Ostrom, RS; Pala, R; Sherpa, RT; Wachten, D | 1 |
Arima, H; Goto, K; Hirano, T; Ishikawa, SE; Motozawa, T; Mouri, M; Watanabe, R | 1 |
B, N; Jayadeep, S; Khan, MF; Pai, K; Varma, M; Vidyasagar, S | 1 |
Capasso, G; Cordat, E; Costanzo, V; Guarino, S; Iervolino, A; Jelen, S; La Manna, A; Marzuillo, P; Miraglia Del Giudice, E; Perna, AF; Prosperi, F; Suzumoto, Y; Trepiccione, F; Zacchia, M | 1 |
Alukal, JJ; John, S; Thuluvath, PJ | 1 |
de Jong-Laird, A; Kabra, M; Lindner, U; Pose-Reino, A; Runkle de la Vega, I | 1 |
Doi, T; Fukahara, K; Imamura, T; Kinugawa, K; Yamashita, S; Yokoyama, S; Yoshimura, N | 1 |
Kimura, Y; Kusumi, F; Matsumoto, A; Matsuyama, S; Minami, R; Ohana, M; Okano, A; Ozawa, T; Takeda, Y; Ueo, T | 1 |
Aihara, M; Fujiki, H; Hattori, K; Isakari, Y; Mizuguchi, H; Nagano, K; Ohmoto, K; Takeshita, Y; Yamada, Y; Yamamoto, M; Yamamura, Y | 1 |
Kokubu, N; Kouzu, H; Nagano, N; Noto, T; Osanami, A; Tanno, M | 1 |
Cao, X; Chen, T; Fu, K; Guo, D; Hu, H; Liu, H; Ren, Y; Su, L; Wang, P; Yuan, H; Zhang, Y; Zhao, W | 1 |
Torres, VE; Zhou, JX | 1 |
Bird-Lieberman, G; Bockenhauer, D; Gilbert, RD; Hoogenboom, L; Kumaran, A; Moon, RJ; Singh, J; Soliman, M | 1 |
Gärtner, F; Jansen, O; Laudes, M; Reinke, LM; Rohmann, N; Schreiber, S; Schulte, DM; Seoudy, AK | 1 |
Baba, K; Horikirizono, H; Igase, M; Kambayashi, S; Kimura, K; Mizuno, T; Okuda, M; Tamura, Y; Yamamoto, H | 1 |
23 review(s) available for tolvaptan and pituitrin
Article | Year |
---|---|
Role of vasopressin antagonists in the management of acute decompensated heart failure.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Stroke Volume; Tolvaptan; Treatment Outcome; Vasoconstriction; Vasopressins | 2005 |
Vasopressin receptor antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Clinical Trials as Topic; Diabetes Insipidus, Nephrogenic; Fibrosis; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Pyrroles; Receptors, Vasopressin; Sodium; Tolvaptan; United States; United States Food and Drug Administration; Vasopressins | 2006 |
Vaptans and the treatment of water-retaining disorders.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Tolvaptan; Vasopressins; Water | 2006 |
Vasopressin antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Binding Sites; Cardiovascular Diseases; Clinical Trials as Topic; Hormone Antagonists; Humans; Indoles; Pyrroles; Pyrrolidines; Tolvaptan; Vasopressins; Water-Electrolyte Imbalance | 2006 |
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Tolvaptan; Vasopressins | 2006 |
Hyponatremia and vasopressin antagonism in congestive heart failure.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2007 |
Vasopressin receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2006 |
[Etiology, diagnostics and therapy of hyponatremias].
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Blood Volume; Brain Diseases; Central Nervous System; Chronic Disease; Demeclocycline; Demyelinating Diseases; Diagnosis, Differential; Diuretics; Extracellular Fluid; Furosemide; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lithium Compounds; Morpholines; Osmolar Concentration; Osmosis; Pyrroles; Severity of Illness Index; Sodium; Spiro Compounds; Time Factors; Tolvaptan; Vasopressins | 2008 |
Hyponatremia in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hyponatremia; Prognosis; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2009 |
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.
Topics: Angiotensin II; Animals; Antidiuretic Agents; Antihypertensive Agents; Benzazepines; Biomarkers; Bosentan; Catecholamines; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Peptides, Cyclic; Renin-Angiotensin System; Sulfonamides; Sympathetic Nervous System; Tolvaptan; Treatment Outcome; Vasopressins | 2010 |
Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
Topics: Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Neurotransmitter Agents; Pyrroles; Tolvaptan; Vasopressins | 2010 |
Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?
Topics: Acute Disease; Animals; Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Hyponatremia; Prognosis; Pyrroles; Tolvaptan; Vasoconstriction; Vasopressins | 2011 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
Tolvaptan for heart failure patients with volume overload.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Edema, Cardiac; Heart Failure; Humans; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2011 |
[Tolvaptan (vasopressin receptor antagonist)].
Topics: Benzazepines; Cardiomyopathy, Dilated; Diuretics; Heart Failure; Humans; Tolvaptan; Vasopressins | 2011 |
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Topics: Animals; Benzazepines; Disease Progression; Humans; Hypertension, Renal; Incidence; Prevalence; Renal Insufficiency, Chronic; Tolvaptan; Vasopressins | 2013 |
Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Heart Failure; Humans; Hyponatremia; Prospective Studies; Tolvaptan; Vasopressins | 2014 |
Management of ascites in cirrhotic patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Ascites; Benzazepines; Diuretics; Humans; Japan; Liver Cirrhosis; Practice Guidelines as Topic; Receptors, Vasopressin; Signal Transduction; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Tolvaptan; Vasopressins | 2017 |
Vasopressin and Vasopressin Antagonists in Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Glycopeptides; Heart Failure; Hemodynamics; Humans; Hyponatremia; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2017 |
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Topics: Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Child; Cyclic AMP; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Signal Transduction; Tolvaptan; Vasopressins | 2018 |
Polycystic Kidney Disease and the Vasopressin Pathway.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Vasopressins | 2017 |
Hyponatremia in Cirrhosis: An Update.
Topics: Acute Kidney Injury; Acute-On-Chronic Liver Failure; Albumins; Antidiuretic Hormone Receptor Antagonists; Ascites; Fluid Therapy; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Hypertension, Portal; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Renin-Angiotensin System; Saline Solution, Hypertonic; Splanchnic Circulation; Tolvaptan; Vasodilation; Vasopressins | 2020 |
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Renal Insufficiency; Tolvaptan; United States; Vasopressins | 2023 |
9 trial(s) available for tolvaptan and pituitrin
Article | Year |
---|---|
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cross-Over Studies; Diuretics; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Placebos; Potassium; Sodium; Tolvaptan; Urination; Vasopressins; Water; Water-Electrolyte Balance | 2006 |
Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Benzazepines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neurophysins; Protein Precursors; Tablets; Thirst; Tolvaptan; Urination; Vasopressins | 2007 |
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Topics: Aged; Aged, 80 and over; Benzazepines; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Revascularization; Pacemaker, Artificial; Prospective Studies; Tolvaptan; Vasopressins | 2008 |
A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure, Systolic; Humans; Male; Middle Aged; Statistics as Topic; Stroke Volume; Tolvaptan; Vasopressins; Ventricular Function, Left | 2011 |
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Topics: Aged; Benzazepines; Female; Follow-Up Studies; Heart Failure; Humans; Inpatients; Kaplan-Meier Estimate; Lymphocyte Count; Male; Middle Aged; Predictive Value of Tests; Prognosis; Regression Analysis; Stroke Volume; Tolvaptan; Vasopressins | 2012 |
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.
Topics: Aged; Aged, 80 and over; Benzazepines; Clinical Protocols; Double-Blind Method; Europe; Europe, Eastern; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Internationality; Male; Middle Aged; North America; Patient Selection; Prospective Studies; South America; Survival Rate; Tolvaptan; Treatment Outcome; Vasopressins | 2013 |
Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Deamino Arginine Vasopressin; Double-Blind Method; Exercise; Female; Hormone Antagonists; Humans; Male; Middle Aged; Neurophysins; Osmolar Concentration; Physical Endurance; Plasma Volume; Protein Precursors; Receptors, Vasopressin; Running; Signal Transduction; Sodium; Sweat; Sweat Glands; Sweating; Thirst; Time Factors; Tolvaptan; Vasopressins; Water-Electrolyte Balance; Weight Loss; Young Adult | 2014 |
Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.
Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Body Water; Brachial Artery; Cross-Over Studies; Double-Blind Method; Female; Humans; Kidney; Male; Nitric Oxide; omega-N-Methylarginine; Placebo Effect; Reference Values; Sodium; Tolvaptan; Vasopressins; Young Adult | 2014 |
Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Japan; Male; Middle Aged; Tolvaptan; Treatment Outcome; Vasopressins; Young Adult | 2021 |
29 other study(ies) available for tolvaptan and pituitrin
Article | Year |
---|---|
Aminocarbonylation route to tolvaptan.
Topics: Benzazepines; Catalysis; Chemistry, Pharmaceutical; Palladium; Tolvaptan; Vasopressins | 2007 |
Introduction: Vasopressin therapy.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Heart Failure; Humans; Hyponatremia; Sodium; Tolvaptan; Vasopressins | 2009 |
The vaptans ante portas: a status report.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hyponatremia; Tolvaptan; Treatment Outcome; Vasopressins | 2009 |
Hyponatremia: vasopressin antagonists in hyponatremia: more data needed.
Topics: Benzazepines; Clinical Trials as Topic; Drug Resistance; Humans; Hyponatremia; Tolvaptan; Vasopressins | 2011 |
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.
Topics: Adult; Aged; Amiloride; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blotting, Western; Cell Proliferation; Cells, Cultured; Chlorides; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; Diuretics; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Renal Agents; Tolvaptan; Vasopressins | 2011 |
V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Topics: Amino Acid Substitution; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Membrane; Child; Child, Preschool; Chlorocebus aethiops; COS Cells; Diabetes Insipidus, Nephrogenic; Humans; Male; Mutation, Missense; Neurophysins; Protein Precursors; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2012 |
Antidiuretic hormone antagonist to reduce cystine stone formation.
Topics: Adult; Benzazepines; Cystinuria; Female; Humans; Kidney Calculi; Male; Middle Aged; Secondary Prevention; Tolvaptan; Vasopressins | 2012 |
Are all clinical trial sites created equal?
Topics: Benzazepines; Female; Heart Failure; Humans; Male; Patient Selection; Tolvaptan; Vasopressins | 2013 |
Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Brain; Gene Expression; Hypertension; Hypothalamus; Mice; Mice, Transgenic; Receptors, Vasopressin; Renin-Angiotensin System; Tolvaptan; Vasopressins | 2013 |
Dehydration effects of a V2 antagonist on endolymphatic hydrops in guinea pigs.
Topics: Administration, Oral; Administration, Topical; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Endolymphatic Hydrops; Endolymphatic Sac; Female; Guinea Pigs; Meniere Disease; Osmolar Concentration; Receptors, Vasopressin; Tolvaptan; Vasopressins; Water-Electrolyte Balance | 2016 |
Tolvaptan regulates aquaporin-2 and fecal water in cirrhotic rats with ascites.
Topics: Animals; Aquaporin 2; Ascites; Benzazepines; Carbon Tetrachloride; Colon; Diarrhea; Dose-Response Relationship, Drug; Feces; Liver Cirrhosis, Experimental; Male; Rats, Sprague-Dawley; Sodium; Time Factors; Tolvaptan; Vasopressins; Water | 2016 |
Predictors for Tolvaptan Treatment and Future Perspectives.
Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Arginine; Benzazepines; Biomarkers; Diuresis; Dose-Response Relationship, Drug; Evidence-Based Medicine; Heart Failure; Humans; Predictive Value of Tests; Prognosis; Renin-Angiotensin System; Sensitivity and Specificity; Severity of Illness Index; Tolvaptan; Treatment Outcome; Vasopressins | 2016 |
[Current options of treatment of hyponatremia].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Europe; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Receptors, Vasopressin; Sodium; Tolvaptan; Vasopressins | 2016 |
Secondary resistance to tolvaptan in two patients with SIAD due to small cell lung cancer.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drug Resistance; Fatal Outcome; Female; Genetic Diseases, X-Linked; Humans; Inappropriate ADH Syndrome; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Sodium; Tolvaptan; Vasopressins | 2018 |
A diuretic-sparing strategy to facilitate deactivation of vasopressin secretion.
Topics: Acute Kidney Injury; Animals; Diuretics; Heart Failure; Humans; Rats, Wistar; Tolvaptan; Vasopressins | 2018 |
Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High?
Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Hyponatremia; Inappropriate ADH Syndrome; Tolvaptan; Vasopressins | 2018 |
Trimethylamine-N-oxide (TMAO) increased aquaporin-2 expression in spontaneously hypertensive rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Blood Pressure; Hypertension; Kidney Medulla; Male; Methylamines; Osmolar Concentration; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tolvaptan; Vasopressins | 2019 |
Sensory primary cilium is a responsive cAMP microdomain in renal epithelia.
Topics: Adenylyl Cyclases; Animals; Calcium; Cell Line; Cilia; Colforsin; Cyclic AMP; Cytosol; Dogs; Epithelial Cells; Gene Knockdown Techniques; Isoenzymes; Membrane Microdomains; Mice; Receptors, Vasopressin; Signal Transduction; Stress, Mechanical; Swine; Tolvaptan; Vasopressins | 2019 |
Syndrome of inappropriate antidiuretic hormone release as the initial presentation of adenocarcinoma of the colon.
Topics: Adenocarcinoma; Colon; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Tolvaptan; Vasopressins | 2020 |
Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cell Line; Cell Membrane; Chlorocebus aethiops; COS Cells; Diabetes Insipidus, Nephrogenic; Dogs; Endoplasmic Reticulum; Humans; Madin Darby Canine Kidney Cells; Male; Mutation; Protein Transport; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2020 |
Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Germany; Humans; Hyponatremia; Inappropriate ADH Syndrome; Retrospective Studies; Spain; Tolvaptan; Vasopressins | 2021 |
Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Biomarkers; Body Fluids; Cardiac Surgical Procedures; Female; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Postoperative Care; Prospective Studies; Tolvaptan; Vasopressins | 2021 |
[A case of SIADH due to pancreatic cancer was improved by tolvaptan].
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Inappropriate ADH Syndrome; Male; Pancreatic Neoplasms; Quality of Life; Tolvaptan; Vasopressins | 2022 |
[Tolvaptan, a vasopressin V
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cyclic AMP; Cysts; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Vasopressins | 2022 |
Early Commencement and Long-Term Continuation of Tolvaptan Treatment Attenuate Functional Impairment of Renal Vasopressin V2 Receptors and Improve Clinical Outcomes in Patients with Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2023 |
Structure-Affinity and Structure-Kinetic Relationship Studies of Benzodiazepine Derivatives for the Development of Efficacious Vasopressin V
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidiuretic Hormone Receptor Antagonists; Benzodiazepines; Humans; Hypnotics and Sedatives; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2023 |
Syndrome of inappropriate secretion of anti-diuretic hormone due to hypothalamic hamartoma: use of tolvaptan.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Humans; Hyponatremia; Inappropriate ADH Syndrome; Seizures; Tolvaptan; Vasopressins | 2023 |
Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Pituitary Gland, Posterior; Tolvaptan; Vasopressins | 2023 |
Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dog Diseases; Dogs; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Sodium; Tolvaptan; Vasopressins | 2023 |